Testing for the genetic anomaly TMPRSS2:ERG in conjunction with use prostate cancer antigen 3 (PCA3) is better at predicting the presence of prostate cancer (PCa) than either marker alone, according to a report in Science Translational Medicine (2011;3:94ra72).

In 1,321 men with elevated PSA levels, urine TMPRSS2:ERG was associated with indicators of clinically significant cancer at biopsy and prostatectomy, including tumor size, high Gleason score at prostatectomy, and upgrading of Gleason score at prostatectomy.

When combined with urine PCA3 testing, TMPRSS2:ERG improved the performance of the multivariate Prostate Cancer Prevention Trial risk calculator in predicting PCa on biopsy.

Continue Reading